SavedAdd your journal

Journals / Marmara Medical Journal / 2008 / Cilt: 21 - Sayı: 1

-

75 YAŞ VE ÜZERİ LOKAL İLERİ VE METASTATİK KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE PRİMER VE PALYATİF TEDAVİ OLARAK RADYOTERAPİ UYGULAMASI: 45 VAKANIN DEĞERLENDİRİLMESİ VE LİTERATÜR İNCELEMESİ

Görkem AKSU
Merdan FAYDA
Mert SAYNAK
Esra KAYTAN SAGLAMER
Ethem NEZİH ORAL
Ahmet KİZİR
Ahmet KARADENİZ
Pages
11–20
Publication Date
2015-06-23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Yöntem: Yetmiş beş yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi. Medyan yaş 78 idi (75-93). Otuz dört hasta Evre IIIB (75%), 11 hasta (25%) ise Evre IV olarak evrelendirildi. Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.

🔖

Cite This Article

AKSU, G., FAYDA, M., SAYNAK, M., SAGLAMER, E. K., ORAL, E. N., KİZİR, A., KARADENİZ, A. (2015). -. Marmara Medical Journal, Cilt: 21 - Sayı: 1, 11–20. https://ajindex.com/articles/688465

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Lonardi F, Coeli M, Pavanato G, Adami F, Gioga G, Campostrini F. Radiotherapy for non-small cell lung cancer in patients aged 75 and over, safety, effectiveness and possible impact on survival. Lung Cancer 2000; 28: -50. Tombolini V, Bonanni A, Donato V, et al. Radiotherapy alone in elderly patients with medically inoperable stage IIIA and IIIB non-small cell lung cancer. Anticancer Res; 20,:4829-4833.
  2. Rengan R, Rosenzweig, KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;60:741-747.
  3. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Longterm survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702–709.
  4. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618–1626.
  5. Borges, M., Sculier, JP., Paesmans, M., et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable nonsmall cell lung cancer (NSCLC). Lung Cancer 1996;16: –33. Stanley, KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst;65:25–32.
  6. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy L, Retchin SM. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer 1998;83: 1930–1937.
  7. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995;13:235–252.
  8. Jeremic B, Shibamoto Y. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer; 13: 21–30.
  9. Langer C, Hsu C, Curran D, et al. Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51: –21. Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of Stage I non- small cell lung cancer in a geriatric population. Lung Cancer 2001; 32: –79. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative On